Overview

Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the antiviral activity of two treatment groups for HIV chronic infection: a QD regimen of didanosine, lamivudine and efavirenz versus a BID regimen of zidovudine, lamivudine and efavirenz. Both will be administered with food in the starting treatment of human immunodeficiency virus infection at Week 48.

Phase:

Phase 4

Details

Lead Sponsor:

Clinical Trial Agency of HIV Study Group

Treatments:

Didanosine
Efavirenz
Lamivudine
Zidovudine